ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

This Phase 2, open label, study with safety lead in of oral talazoparib in combination with ZEN003694 given daily in 28-day cycles will enroll patients with recurrent ovarian, fallopian tube or primary peritoneal carcinoma.

Trial Details

NCT ID
NCT05071937
Phase
PHASE2
Sponsor
Alexander B Olawaiye, MD
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • ZEN003694
  • Talazoparib
Locations (sample)
  • Pittsburgh, Pennsylvania, United States|40.44062,-79.99589

Key Eligibility Criteria

  • Females age ≥ 18 years (at time of signing informed consent)
  • ECOG status 0 or 1
  • Pathologically documented ovarian, fallopian tube, or primary peritoneal carcinoma.
  • Prior therapy with PARPi either as maintenance or therapeutic settings.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →